Cellectar (CLRB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Cellectar (CLRB)

The historical EV/EBITDA chart for Cellectar Biosciences (CLRB), which currently stands at 0.00, is based on the exclusivity of PDC isotope delivery technologies within tumors. Integration into oncology center environments ensures patient loyalty and FDA support. Meanwhile, the business relies on the development of radiopharmaceuticals for blood therapy, where success depends on patents and clinical trials rather than market cycles.

CLRB Cellectar Biosciences Inc: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026

CLRB (cellectar.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Cellectar|CLRB - Fair Value Consensus
- market capitalization indicators:
Market Value Cellectar Corp|CLRB - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Cellectar Biosciences|CLRB - Accounting Capitalization|Market Capitalization to Book Value Ratio cellectar.com|CLRB - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Cellectar Biosciences|CLRB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Cellectar Biosciences, Inc.|CLRB - Company Debts|Debt to Book Capitalization Ratio Cellectar Corp|CLRB - Long-Term Debt|Company Short-Term Debts Cellectar Biosciences|Quick Liquidity Indicator cellectar.com
- business earnings and investment ratios data:
CLRB - Company Net Income|Future Profit Cellectar Biosciences|CLRB - Company Value to Net Income|Projected Price to Earnings Cellectar Biosciences|CLRB - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Cellectar Corp|CLRB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Cellectar Biosciences|CLRB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months cellectar.com|CLRB - Earnings per share increase in current year|Earnings growth forecast for next year Cellectar Biosciences
Summary company analytics:CLRB (Cellectar)
Original product of Cellectar Biosciences, Inc.

To minimize risks, it is essential for investors to monitor the ratio of Cellectar Biosciences (CLRB) enterprise value to its operational earnings before interest, taxes, depreciation, and amortization. Analyzing the EV/EBITDA multiple chart allows for an assessment of the company's stability amid the development of targeted radioisotopes for the treatment of Waldenström macroglobulinemia, confirming the capital's ability to service debt while preparing for drug commercialization.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple lixte.com LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)